Related Experiment Videos
Medullary thyroid carcinoma.
1Endocrine and Oncologic Surgery, Siteman Cancer Center, Washington University School of Medicine, Box 8109, 660 South Euclid, St. Louis, MO 63110, USA. moleyj@msnotes.wustl.edu
Current Treatment Options in Oncology
|August 29, 2003
Summary
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine cancer. While surgery can cure some patients, effective systemic treatments are lacking, highlighting the need for new therapies targeting RET mutations.
Area of Science:
- Oncology
- Endocrinology
- Genetics
Background:
- Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy with hereditary and sporadic forms.
- MTC is associated with multiple endocrine neoplasia type 2 syndromes.
- Calcitonin measurement aids in tumor detection and therapy monitoring.
Purpose of the Study:
- To summarize the current understanding of Medullary Thyroid Carcinoma (MTC).
- To highlight challenges in MTC treatment and identify future therapeutic directions.
Main Methods:
- Review of existing literature on MTC pathophysiology, clinical presentation, and treatment outcomes.
- Analysis of the role of genetic mutations, particularly RET, in MTC development.
- Evaluation of current and emerging therapeutic strategies.
Main Results:
- Surgical intervention offers cure for select MTC patients, including those with hereditary forms undergoing prophylactic thyroidectomy and those with recurrent nodal disease.
- Mortality is linked to tumor invasion and distant metastases.
- No consistently effective systemic therapy currently exists for MTC.
Conclusions:
- Early diagnosis and surgical intervention are crucial for improving outcomes in MTC.
- The prevalence of RET mutations underscores the potential for targeted therapies.
- Clinical trials investigating tyrosine kinase inhibitors and other agents are vital for developing effective systemic treatments for MTC.